Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page’s displayed release/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a site/system update rather than a change to the study record content.SummaryDifference0.1%

- Check9 days agoChange DetectedRevision number updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedRemoved Hepatocellular carcinoma from the Conditions list and removed the Genetic and Rare Diseases Information Center resource under Resources.SummaryDifference0.2%

- Check38 days agoChange DetectedAdded the MeSH term 'Hepatocellular carcinoma' and a link to the Genetic and Rare Diseases Information Center; updated page revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check53 days agoChange DetectedUpdated site revision from v3.4.2 to v3.4.3. No visible changes to the study details page.SummaryDifference0.1%

- Check74 days agoChange DetectedUpdated the site revision from v3.4.1 to v3.4.2; no user-facing content or functionality appears to be affected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.